Treace to Present at 43rd Annual J.P. Morgan Healthcare Conference: A Look into the Future of Bunion Correction

Treace Medical Concepts, Inc. (TMCI), a leading orthopedic medical device company specializing in the surgical treatment of bunions and related midfoot deformities, has announced that it will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference. This prestigious event, taking place from January 9-12, 2023, brings together industry leaders, investors, and innovators to discuss the latest trends and developments in the healthcare sector. Treace's presentation, scheduled for January 11, 2023, at 10:30 a.m. Eastern Time, is set to provide valuable insights into the company's recent advancements and future growth prospects.



Treace's commitment to advancing the standard of care for bunion correction is evident in its ongoing investment in research and development. The company's flagship product, the Lapiplasty® 3D Bunion Correction™ System, has been a game-changer in the market, offering a comprehensive solution for the surgical management of hallux valgus deformities. Treace's innovative approach to bunion correction addresses the root cause of the deformity by surgically correcting all three planes of the bunion deformity and securing the unstable joint, helping patients return to their active lifestyles more quickly and with improved long-term outcomes.



One of the key highlights of Treace's presentation at the J.P. Morgan Healthcare Conference will be the company's new product innovations, including the Nanoplasty™ MIS 3D Osteotomy System and IntelliGuide™ PSI Cut Guides. These cutting-edge solutions are designed to further enhance the precision and personalization of bunion correction procedures, offering surgeons more minimally invasive and customized options for their patients. The Nanoplasty™ MIS 3D Osteotomy System enables surgeons to perform bunion correction through smaller incisions, reducing tissue trauma and minimizing scarring. The IntelliGuide™ PSI Cut Guides, on the other hand, facilitate personalized surgical planning by providing surgeons with precise, patient-specific guides for bone cuts, ensuring optimal correction of the bunion deformity.

Treace's commitment to evidence-based medicine is another crucial aspect of the company's success. The interim data from the ALIGN3D™ and Mini3D™ Lapiplasty® clinical studies, to be presented at the American Orthopaedic Foot & Ankle Society Annual Meeting 2024, demonstrates the sustained positive outcomes and favorable clinical and patient-reported outcomes of Treace's Lapiplasty® Procedure. These results validate the effectiveness and durability of Treace's approach to bunion correction, further solidifying the company's position in the market.



In conclusion, Treace Medical Concepts' presentation at the 43rd Annual J.P. Morgan Healthcare Conference is an exciting opportunity for investors and industry professionals to learn more about the company's innovative product portfolio and commitment to advancing the standard of care for bunion correction. With its cutting-edge solutions and strong clinical data, Treace is well-positioned to continue its growth trajectory and maintain its competitive edge in the orthopedic medical device market. As the company continues to invest in research and development, it is poised to shape the future of bunion correction and improve the lives of patients worldwide.